ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Nuvalent sets out its two-pronged strategy
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
Mersana shows that B7-H4 expression matters
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
